Challenge yourself with this CME/CE-accredited Interactive Case Challenge. Explore evidence-based strategies for the long-term management of MASH, with a focus on sustained response and comorbidity control. Learn how to incorporate incretin-based therapies and apply updated guidelines and patient-specific factors to optimize treatment outcomes over time.
Learning objectives:
Upon completion of this activity, participants should be able to:
- Identify the role of incretin-based therapies in the management of MASH and cardiometabolic comorbidities
- Integrate the latest guidelines, evidence, and patient-specific factors into comprehensive treatment plans for patients with MASH
Faculty:
Kathleen Corey, MD, MPH, MMSc
Director, MASLD Program
Massachusetts General Hospital
Associate Professor
Harvard Medical School
Boston, Massachusetts
Supporters:
Supported by an educational grant from Novo Nordisk.
Sponsor:
Provided by Clinical Care Options, LLC in partnership with AGA
Released: July 13, 2025
Expiration: July 14, 2026
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Primary Author
Kathleen Corey, MD, MPH, MMSc, has no relevant financial relationships to disclose.
The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose, except Amy Butts, PA-C, DFAAPA, BC-ADM, CDCES, as noted below:
Amy Butts, PA-C, DFAAPA, BC-ADM, CDCES: consultant/advisor/speaker: Abbott, Novo Nordisk, Xeris.
